SAN FRANCISCO (GenomeWeb News) - Thermo Fisher Scientific intends to increase its R&D spending in 2010 and expand its operating footprint in a handful of low-cost regions around the world.

Speaking today to investors at the JP Morgan Healthcare Conference held here, Thermo President and CEO Marc Casper said that the firm expects its R&D investments to target three key areas: mass spectrometry, specialty diagnostics, and bioscience reagents. However, he did not provide an estimate for the planned increased investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.

Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.